Back to Stakeholders
Research, Drug Development & Manufacturing
Research, Drug Development & ManufacturingCompany-Led Drug Development & CommercializationEarly-Stage Translational Research (Pre-Clinical)
Research, Drug Development & ManufacturingCompany-Led Drug Development & Commercialization
Lead program: Pre-clinical

Alvarius Pharmaceuticals

1 Drug Candidate

Alvarius Pharmaceuticals is an Irish bio-pharmaceutical company developing 5-MeO-DMT-based therapies for addiction and substance use disorders. Founded in 2021 and based in Dublin, the company conducts preclinical studies in collaboration with University College Dublin, combining acute 5-MeO-DMT administration with guided psychotherapy. Alvarius raised €5.5M in 2023 and has filed one patent.

Development Programmes

1

5-MeO-DMT

5-MeO-DMT
Pre-clinical
Substance Use Disorders (SUD)

Substance use disorders (cocaine, heroin, alcohol)

Programme Tracker

Substance Use Disorders (SUD)

Primary: EU (EMA)
Pre-clinicalActive

Preclinical stage; 3D cerebral organoid models for stimulant/opioid/alcohol damage reversal; Phase 1 was planned Q2 2024 but no public confirmation it started; Dublin, Ireland based

Milestones

phase-1-initiated

Planned

Phase 1 safety study announced for Q2 2024 — safety in humans plus addiction benefit evaluation; status unconfirmed

Why it matters: If Phase 1 started, it would be one of the first clinical trials of 5-MeO-DMT for addiction. However, no ClinicalTrials.gov registration found and no public confirmation of trial initiation. One patent filed.

Watch next: Phase 1 trial registration; clinical site disclosure; any press release confirming trial start

Funding milestone

Completed

Actual: Jan 1, 2021

Founded in Dublin, Ireland; seed round ~EUR 2.7M (~$3.28M) from Re:Mind Capital (Christian Angermayer); total raised EUR 5.5M

Why it matters: Re:Mind Capital (Angermayer) is one of the most active psychedelic investors globally (also backed ATAI, Compass). EUR 5.5M total provides preclinical runway. Company collaborates with University College Dublin (UCD) — not UC Davis.

preclinical-data

Completed

Actual: Jun 1, 2023

Preclinical data: 5-MeO-DMT reverses stimulant damage in 3D cerebral organoid models; genomic/proteomic profiling completed for stimulant, opioid, and alcohol addiction models

Why it matters: 3D cerebral organoids provide more physiologically relevant models than standard 2D cell cultures. Demonstrating structural reversal of stimulant-induced neuronal damage supports the neuroplasticity hypothesis for 5-MeO-DMT in addiction. Library of 5-MeO-DMT analogues also under investigation.

Recorded Events

Jun 1, 2023: preclinical-data

Jan 1, 2021: Funding milestone

Quick Facts

Type
Private Biotech
Founded
2021
Lead Stage
Pre-clinical
Website
Visit